Navigation Links
The prevalence and impact of arthritis and other rheumatic conditions in the United States
Date:1/2/2008

Arthritis is the most common cause of disability in the United States. Over the next 25 years as the Baby Boom generation continues to age, the toll of this disease will escalate. To have a clear picture of the looming disease burden and its impact on our nations health care and public health systems, estimating disease prevalencethe number of people affected by any form of arthritisis critical.

The National Arthritis Data Workgroup was formed to provide a single source of national data on various rheumatic conditions. Supported by the National Institutes of Health, the Centers for Disease Control, the American College of Rheumatology, and the Arthritis Foundation, its epidemiology experts use the best studies available to determine disease prevalence, assess potential disease impact, and identify gaps in our understanding of disease rates, populations, and social implications. In the January 2008 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis), the group presents its latest report on the troubling state of arthritis in America.

Based on analyses of population estimates from the Census Bureau, responses from national surveys, and findings from scores of community-based studies across the country, the National Arthritis Data Workgroup offers an unsettling snapshot of the 2005 (and future) burden of arthritis. Some key findings of the study include:

  • Overall arthritis: More than 21 percent of U.S. adultsover 46 million people-- have arthritis or other rheumatic condition diagnosed by a doctor. Nearly two-thirds of arthritis patients are younger than 65. More than 60 percent are women. Disease rates are similar for whites and African-Americans and higher than the rates for Hispanics. By 2030, the number of people with arthritis is projected to increase to nearly 67 millionan increase of 40 percent.

    '/>"/>

Contact: Amy Molnar
amolnar@wiley.com
Wiley-Blackwell
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Prevalence of COPD Greater Than Thought
2. A low prevalence of H pylori in HIV-positive patients
3. Asymptomatic peripheral artery disease prevalence is rising
4. CDC Reports Prevalence of Worms Transmitted by Dogs and Cats to Humans is Higher Than Previously Understood
5. Miscarriage myths persist despite prevalence of medical information
6. Insurance Impacts Laryngeal Cancer Detection
7. HIVs impact in Zimbabwe explored in new research
8. NYU study points to lasting impact of mild hearing loss on neurological processes
9. Limiting Residents Hours Has Little Impact on Patient Mortality
10. Just Completed Studies Reveal Impact of New Medicare Reimbursement Regulations
11. PA Health Department Survey Shows Impact of Income, Gender, Other Factors on Health and Access to Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... The Biofeedback Federation of Europe annual meeting is ... Italy and is hosted by the Salesian Pontifical University. ... wide variety of topics such as ADHD, anxiety, headaches ... athletes. The scientific program will feature the latest in ... clients to see what is going on in their ...
(Date:12/26/2014)... WA (PRWEB) December 26, 2014 “Many ... deal with personal injury claim issues and phone calls ... recently released an article featuring their free eBook ... exceptionally helpful eBook on pedestrian and bicycle auto accident ... attorney is fully capable of professionally handling their case ...
(Date:12/26/2014)... December 26, 2014 Pentec Health, Inc. ... the state of Pennsylvania for 2014. The awards program, ... programs of its kind in the country. The program ... Pennsylvania Department of Community and Economic Development, the Pennsylvania ... and the Central Penn Business Journal. , ...
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... December 26, 2014 This is a ... the global Sterilizers industry with a focus on the ... market status of the Sterilizers manufacturers and is a ... individuals interested in the industry. This report provides a ... and manufacturing technology. In this part, the report presents ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3
... Toronto Stock Exchange Symbol: CYT, MONTREAL, Nov. ... global leader in cryotherapy products to treat cardiac,arrhythmias, ... of,CryoCath, will present at both the Piper Jaffray ... on Healthcare Conference. The Piper Jaffray,Conference presentation will ...
... Trigger Milestone Payments Totaling $1 Million to ... ... PCOP ), an innovator in the discovery and development of ... compounds for advancement in its alliance with GlaxoSmithKline (NYSE:,GSK), through its ...
... movie is a,psychological thriller that tells the story of a ... but paralyzed,during heart surgery., It has been 30 years ... ,Coma, is the gripping story of patients,who check into a ... "Five years after the book and movie, I still ...
... of Hematology ... (ASH) Annual Meeting, SEATTLE, Nov. ... announced it intends to utilize the,results of the phase III first-line ... submission to the United States Food,and Drug Administration (FDA) for potential ...
... Today at 10:30 CET, AMSTERDAM, November 27 ... the field of human gene therapy,today announced it ... the,development of AAV-mediated insulin-like growth factor I (IGF-I) ... CET today, the company,s,management will hold a conference ...
... is a close relationship between infection outbreaks on teeth and ... of hair loss which has an unknown origin. Alopecia areata ... on the body. The disease occurs in males and females ... out 1000 people. , Research by professors Jos Antonio Gil ...
Cached Medicine News:Health News:CryoCath to present at Piper Jaffray and BMO Healthcare conferences 2Health News:Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds 2Health News:Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds 3Health News:Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds 4Health News:Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds 5Health News:'Awake' the Movie Highlights the Need for 'Goldilocks' Anesthesia, Says Dr. Barry L. Friedberg, Developer of Bispectral Index (BIS) Monitored Propofol Ketamine Sedation, Now Trademarked as Minimally Invasive Anesthesia (MIA)(R) 2Health News:'Awake' the Movie Highlights the Need for 'Goldilocks' Anesthesia, Says Dr. Barry L. Friedberg, Developer of Bispectral Index (BIS) Monitored Propofol Ketamine Sedation, Now Trademarked as Minimally Invasive Anesthesia (MIA)(R) 3Health News:Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008 2Health News:Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008 3Health News:Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008 4Health News:Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008 5Health News:Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008 6Health News:Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis and Reports Strong Progress in AMT-011 With Trial Fully Recruited and European and US Submission On Track for First Half of 2008 2Health News:Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis and Reports Strong Progress in AMT-011 With Trial Fully Recruited and European and US Submission On Track for First Half of 2008 3Health News:Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis and Reports Strong Progress in AMT-011 With Trial Fully Recruited and European and US Submission On Track for First Half of 2008 4Health News:Infection outbreaks on teeth can cause 'alopecia areata' or localized hair loss 2
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
(Date:12/24/2014)... , Dec. 23, 2014  Endo Pharmaceuticals Inc., ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, Inc. ... have submitted a New Drug Application (NDA) for Buprenorphine ... Administration (FDA).  Buprenorphine HCl Buccal Film is under development ... daily, around-the-clock, long-term opioid treatment and for which alternative ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2
... TAXUS(R) Stent shows no additional very late stent ... 4 ,Boston Scientific Corporation (NYSE: BSX ) ... II clinical trial, demonstrating continued,long-term safety and efficacy ... the TAXUS stent showed no additional stent,thrombosis between ...
... investigators at the,European Society of Cardiology Congress 2007 (ESC ... continued to,provide clinical benefits compared to a bare metal ... follow-up with no differences in safety. At five-year ... the,study continued to be significantly less likely than the ...
Cached Medicine Technology:Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 2Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 3Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 2Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 3Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 5
... Releasing the power of clinical information. ... newest generation of clinical connectivity solutions that ... provide effective, high-quality patient care. You will ... be able to share it with your ...
... tool for Clinical Professionals and Researchers., ,S/5 ... easy and efficient way to collect data from ... to days at selectable time intervals. With S/5 ... from the monitor via an interface cable or ...
... Flexible monitoring for intermediate care., ,The ... GE Healthcare Datex-Ohmeda S/5 product line., ,The ... you the power to grow. The new Patient ... hemodynamic measurements up to 12-lead ECG, NIBP, ...
... ,The Datex-Ohmeda S/5 Light Monitor is a ... and critical care areas, in emergency or medium-care ... part of the Datex-Ohmeda S/5 family, the S/5 ... and design shared by all S/5 monitoring products ...
Medicine Products: